Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten public…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
